Biomedicine

Adult B-ALL exhibits significant heterogeneity and poor prognosis compared with the pediatric population. While the complete remission (CR)…

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. This…

Patel, H. N. et al. J. Pharm. Bioallied Sci. 17, S1101–S3 (2025). Article PubMed PubMed Central Google Scholar …

These authors contributed equally: Yiming Qin, Tao Yan, Matthew Yu Heng Wong. School of Clinical Medicine, Beijing Tsinghua…

EHRSHOT database and prediction task The EHR data used in our experiments are from the EHRSHOT benchmark for…

Oxalic acid might do more than just contribute to the formation of kidney stones — it may also be an…

Health system learning We define ‘health system learning’ as learning directly from uncurated data generated during routine clinical…

Adapting prime editing for mammalian histone mutagenesis Mouse canonical histone H3 is encoded by nine H3.1 and three…

Andrew Futreal is a professor and chair in the Department of Genomic Medicine at The University of Texas…

ParticipantsParticipation in BabyScreen+ and gNBS A total of 1139 participants consented to BabyScreen+ research, regardless of whether they…

Design We conducted a pragmatic, multicenter, parallel-group cluster-randomized controlled trial across a network of 16 primary care facilities…

Singhal, K. et al. Large language models encode clinical knowledge. Nature 620, 172–180 (2023). Article CAS PubMed PubMed…

Fixed-dose inotuzumab ozogamicin (INO) combined with Vincristine and Prednisone (VP) regimen as induction therapy for newly diagnosed B-cell acute lymphocytic leukemia (B-ALL): a multi-center, open-label, single-arm, prospective clinical study